MX2019000037A - Metodos para perfilado de fragmentoma de acidos nucleicos libres de celula. - Google Patents
Metodos para perfilado de fragmentoma de acidos nucleicos libres de celula.Info
- Publication number
- MX2019000037A MX2019000037A MX2019000037A MX2019000037A MX2019000037A MX 2019000037 A MX2019000037 A MX 2019000037A MX 2019000037 A MX2019000037 A MX 2019000037A MX 2019000037 A MX2019000037 A MX 2019000037A MX 2019000037 A MX2019000037 A MX 2019000037A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- methods
- dna
- nucleic acids
- free nucleic
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 102000053602 DNA Human genes 0.000 abstract 5
- 108020004414 DNA Proteins 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 2
- 230000004077 genetic alteration Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000392 somatic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Artificial Intelligence (AREA)
- Software Systems (AREA)
- Public Health (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción contempla varios usos de ADN libre de célula. Los métodos proporcionados en la presente pueden usar información de secuencia de una manera global y de macroescala, con o sin información de variantes somáticas, para valorar un perfil de fragmentoma que puede ser representativo de un tejido de origen, enfermedad, progresión, etc. En un aspecto, en la presente se describe un método para determinar la presencia o ausencia de una anormalidad genética en fragmentos de ácido desoxirribonucleico (ADN) de ADN libre de célula obtenido de un sujeto, el método que comprende: (a) construir una distribución multiparamétrica de los fragmentos de ADN sobre una pluralidad de posiciones base en un genoma; y (b) sin tomar en cuenta una identidad base de cada posición base en un primer locus, usar la distribución multiparamétrica para determinar la presencia o ausencia de la anormalidad genética en el primer locus en el sujeto.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359151P | 2016-07-06 | 2016-07-06 | |
| US201662420167P | 2016-11-10 | 2016-11-10 | |
| US201662437172P | 2016-12-21 | 2016-12-21 | |
| US201762489399P | 2017-04-24 | 2017-04-24 | |
| PCT/US2017/040986 WO2018009723A1 (en) | 2016-07-06 | 2017-07-06 | Methods for fragmentome profiling of cell-free nucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000037A true MX2019000037A (es) | 2019-07-10 |
Family
ID=60913158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000037A MX2019000037A (es) | 2016-07-06 | 2017-07-06 | Metodos para perfilado de fragmentoma de acidos nucleicos libres de celula. |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP4322168A3 (es) |
| JP (3) | JP7448310B2 (es) |
| KR (1) | KR102610098B1 (es) |
| CN (1) | CN109689891B (es) |
| AU (1) | AU2017292854B2 (es) |
| BR (1) | BR112019000296A2 (es) |
| CA (1) | CA3030038A1 (es) |
| ES (1) | ES2967443T3 (es) |
| MX (1) | MX2019000037A (es) |
| SG (1) | SG11201811556RA (es) |
| WO (1) | WO2018009723A1 (es) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| EP2854057B1 (en) | 2010-05-18 | 2018-03-07 | Natera, Inc. | Methods for non-invasive pre-natal ploidy calling |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| EP2673729B1 (en) | 2011-02-09 | 2018-10-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| EP3907297A1 (en) | 2011-04-15 | 2021-11-10 | The Johns Hopkins University | Safe sequencing system |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| ES2886507T5 (es) | 2012-10-29 | 2024-11-15 | Univ Johns Hopkins | Prueba de Papanicolaou para cánceres de ovario y de endometrio |
| JP6659575B2 (ja) | 2014-04-21 | 2020-03-04 | ナテラ， インコーポレイテッド | 変異の検出および染色体分節の倍数性 |
| US20180173845A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| ES2960201T3 (es) | 2015-07-23 | 2024-03-01 | Univ Hong Kong Chinese | Análisis de los patrones de fragmentación del ADN acelular |
| WO2017027653A1 (en) | 2015-08-11 | 2017-02-16 | The Johns Hopkins University | Assaying ovarian cyst fluid |
| CN109312400A (zh) | 2016-03-25 | 2019-02-05 | 凯锐思公司 | 合成核酸掺入物 |
| WO2017181202A2 (en) | 2016-04-15 | 2017-10-19 | Natera, Inc. | Methods for lung cancer detection |
| US11485996B2 (en) | 2016-10-04 | 2022-11-01 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| JP7300989B2 (ja) | 2016-12-22 | 2023-06-30 | ガーダント ヘルス， インコーポレイテッド | 核酸分子を解析するための方法およびシステム |
| DK3574108T3 (da) | 2017-01-25 | 2024-09-16 | Univ Hong Kong Chinese | Diagnostisk anvendelse ved brug af nukleinsyrefragment |
| WO2019016353A1 (en) * | 2017-07-21 | 2019-01-24 | F. Hoffmann-La Roche Ag | CLASSIFICATION OF SOMATIC MUTATIONS FROM A HETEROGENEOUS SAMPLE |
| IL319255A (en) | 2017-08-07 | 2025-04-01 | Univ Johns Hopkins | Methods and materials for cancer assessment and treatment |
| WO2019060716A1 (en) | 2017-09-25 | 2019-03-28 | Freenome Holdings, Inc. | SAMPLE EXTRACTION METHODS AND SYSTEMS |
| CA3085933A1 (en) | 2017-12-14 | 2019-06-20 | Tai Diagnostics, Inc. | Assessing graft suitability for transplantation |
| WO2019147663A1 (en) * | 2018-01-24 | 2019-08-01 | Freenome Holdings, Inc. | Methods and systems for abnormality detection in the patterns of nucleic acids |
| EP3762513A1 (en) * | 2018-03-08 | 2021-01-13 | St. Johns University | Circulating serum cell-free dna biomarkers and methods |
| EP3765633A4 (en) * | 2018-03-13 | 2021-12-01 | Grail, Inc. | PROCESS AND SYSTEM FOR THE SELECTION, ADMINISTRATION AND ANALYSIS OF HIGH DIMENSIONAL DATA |
| WO2019178563A1 (en) * | 2018-03-15 | 2019-09-19 | The Board Of Trustees Of Leland Stanford Junior University | Methods using nucleic acid signals for revealing biological attributes |
| CA3095056A1 (en) * | 2018-04-13 | 2019-10-17 | Freenome Holdings, Inc. | Machine learning implementation for multi-analyte assay of biological samples |
| AU2019253112A1 (en) * | 2018-04-13 | 2020-10-29 | Grail, Llc | Multi-assay prediction model for cancer detection |
| JP7573443B2 (ja) | 2018-04-14 | 2024-10-25 | ナテラ， インコーポレイテッド | 循環腫瘍ｄｎａの個別化された検出を用いる癌検出およびモニタリングの方法 |
| CN112888459B (zh) | 2018-06-01 | 2023-05-23 | 格里尔公司 | 卷积神经网络系统及数据分类方法 |
| WO2020006369A1 (en) * | 2018-06-29 | 2020-01-02 | Guardant Health, Inc. | Methods and systems for analysis of ctcf binding regions in cell-free dna |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| US20200075124A1 (en) * | 2018-09-04 | 2020-03-05 | Guardant Health, Inc. | Methods and systems for detecting allelic imbalance in cell-free nucleic acid samples |
| JP7654538B2 (ja) * | 2018-10-08 | 2025-04-01 | フリーノム ホールディングス，インク． | 転写因子プロファイリング |
| GB201818159D0 (en) * | 2018-11-07 | 2018-12-19 | Cancer Research Tech Ltd | Enhanced detection of target dna by fragment size analysis |
| WO2020106893A1 (en) | 2018-11-21 | 2020-05-28 | Karius, Inc. | Direct-to-library methods, systems, and compositions |
| CN113227468A (zh) * | 2018-11-21 | 2021-08-06 | 卡里乌斯公司 | 感染性疾病的检测和预测 |
| US10468141B1 (en) * | 2018-11-28 | 2019-11-05 | Asia Genomics Pte. Ltd. | Ancestry-specific genetic risk scores |
| US11581062B2 (en) | 2018-12-10 | 2023-02-14 | Grail, Llc | Systems and methods for classifying patients with respect to multiple cancer classes |
| ES2968457T3 (es) * | 2018-12-19 | 2024-05-09 | Univ Hong Kong Chinese | Características de los extremos del ADN extracelular circulante |
| EP3899049A1 (en) * | 2018-12-21 | 2021-10-27 | F. Hoffmann-La Roche AG | Identification of global sequence features in whole genome sequence data from circulating nucelic acid |
| CA3122109A1 (en) * | 2018-12-21 | 2020-06-25 | Grail, Inc. | Systems and methods for using fragment lengths as a predictor of cancer |
| WO2020150258A1 (en) * | 2019-01-15 | 2020-07-23 | Luminist, Inc. | Methods and systems for detecting liver disease |
| EP3914731A1 (en) * | 2019-01-24 | 2021-12-01 | Illumina, Inc. | Methods and systems for monitoring organ health and disease |
| CN113661249B (zh) | 2019-01-31 | 2025-07-01 | 夸登特健康公司 | 用于分离无细胞dna的组合物和方法 |
| EP3924503A4 (en) | 2019-02-12 | 2023-03-08 | Tempus Labs, Inc. | DETECTION OF LOSS OF HETEROZYGOTIA OF HUMAN LEUCOCYTE ANTIGEN |
| US11475978B2 (en) | 2019-02-12 | 2022-10-18 | Tempus Labs, Inc. | Detection of human leukocyte antigen loss of heterozygosity |
| WO2020176659A1 (en) * | 2019-02-27 | 2020-09-03 | Guardant Health, Inc. | Methods and systems for determining the cellular origin of cell-free dna |
| WO2020214547A1 (en) * | 2019-04-15 | 2020-10-22 | Natera, Inc. | Improved liquid biopsy using size selection |
| EP4425506A3 (en) | 2019-05-22 | 2024-12-04 | Grail, Inc. | Systems and methods for determining whether a subject has a cancer condition using transfer learning |
| US11939636B2 (en) | 2019-05-31 | 2024-03-26 | Guardant Health, Inc. | Methods and systems for improving patient monitoring after surgery |
| WO2020247263A1 (en) | 2019-06-06 | 2020-12-10 | Natera, Inc. | Methods for detecting immune cell dna and monitoring immune system |
| WO2021007462A1 (en) * | 2019-07-09 | 2021-01-14 | The Translational Genomics Research Institute | METHODS OF DETECTING DISEASE AND TREATMENT RESPONSE IN cfDNA |
| WO2021041968A1 (en) * | 2019-08-28 | 2021-03-04 | Grail, Inc. | Systems and methods for predicting and monitoring treatment response from cell-free nucleic acids |
| CN110706749B (zh) * | 2019-09-10 | 2022-06-10 | 至本医疗科技（上海）有限公司 | 一种基于组织器官分化层次关系的癌症类型预测系统和方法 |
| US11891653B2 (en) | 2019-09-30 | 2024-02-06 | Guardant Health, Inc. | Compositions and methods for analyzing cell-free DNA in methylation partitioning assays |
| EP4041888A4 (en) * | 2019-10-11 | 2023-11-01 | Guardant Health, Inc. | Use of cell free bacterial nucleic acids for detection of cancer |
| CN114746560A (zh) | 2019-11-26 | 2022-07-12 | 夸登特健康公司 | 改进甲基化多核苷酸结合的方法、组合物和系统 |
| CA3163405A1 (en) * | 2019-11-29 | 2021-06-03 | GC Genome Corporation | Artificial intelligence-based chromosomal abnormality detection method |
| CN115151657A (zh) * | 2019-12-20 | 2022-10-04 | 安可济控股有限公司 | 用于疾病检测的方法和系统 |
| US20230042332A1 (en) * | 2019-12-24 | 2023-02-09 | Vib Vzw | Disease Detection in Liquid Biopsies |
| EP4143338A1 (en) | 2020-04-30 | 2023-03-08 | Guardant Health, Inc. | Methods for sequence determination using partitioned nucleic acids |
| EP4154255A4 (en) * | 2020-05-22 | 2024-07-17 | Aqtual, Inc. | METHODS FOR CHARACTERIZING CELL-FREE NUCLEIC ACID FRAGMENTS |
| WO2023282916A1 (en) | 2021-07-09 | 2023-01-12 | Guardant Health, Inc. | Methods of detecting genomic rearrangements using cell free nucleic acids |
| EP4407042A3 (en) | 2020-07-10 | 2024-09-18 | Guardant Health, Inc. | Methods of detecting genomic rearrangements using cell free nucleic acids |
| EP4585697A2 (en) | 2020-07-30 | 2025-07-16 | Guardant Health, Inc. | Methods for isolating cell-free dna |
| EP4205126A1 (en) | 2020-08-25 | 2023-07-05 | Guardant Health, Inc. | Methods and systems for predicting an origin of a variant |
| EP4214329A4 (en) * | 2020-09-17 | 2024-12-04 | The Regents of the University of Colorado, a body corporate | Signatures in cell-free dna to detect disease, track treatment response, and inform treatment decisions |
| US20220154285A1 (en) | 2020-09-30 | 2022-05-19 | Guardant Health, Inc. | Analysis of methylated dna comprising methylation-sensitive or methylation-dependent restrictions |
| EP4232599A1 (en) | 2020-10-23 | 2023-08-30 | Guardant Health, Inc. | Compositions and methods for analyzing dna using partitioning and base conversion |
| EP4251765A1 (en) | 2020-11-30 | 2023-10-04 | Guardant Health, Inc. | Compositions and methods for enriching methylated polynucleotides |
| CN114634982A (zh) * | 2020-12-15 | 2022-06-17 | 广州市基准医疗有限责任公司 | 一种检测多核苷酸变异的方法 |
| EP4015650A1 (en) * | 2020-12-18 | 2022-06-22 | Nipd Genetics Biotech Limited | Methods for classifying a sample into clinically relevant categories |
| WO2022140629A1 (en) | 2020-12-23 | 2022-06-30 | Guardant Health, Inc. | Methods and systems for analyzing methylated polynucleotides |
| WO2022174109A1 (en) | 2021-02-12 | 2022-08-18 | Guardant Health, Inc. | Methods and compositions for detecting nucleic acid variants |
| WO2022204730A1 (en) | 2021-03-25 | 2022-09-29 | Guardant Health, Inc. | Methods and compositions for quantifying immune cell dna |
| EP4347884A1 (en) * | 2021-05-24 | 2024-04-10 | University of Essex Enterprises Limited | Method and system for identifying genomic regions with condition sensitive occupancy/positioning of nucleosomes and/or chromatin |
| KR20220160805A (ko) * | 2021-05-28 | 2022-12-06 | 한국과학기술원 | 조직 특이적 조절지역의 무세포 dna 분포를 이용한 인공지능 기반 암 조기진단 방법 |
| CN113838533B (zh) * | 2021-08-17 | 2024-03-12 | 福建和瑞基因科技有限公司 | 一种癌症检测模型及其构建方法和试剂盒 |
| CA3236814A1 (en) * | 2021-11-17 | 2023-05-25 | Maximilian Diehn | Systems and methods for gene expression and tissue of origin inference from cell-free dna |
| WO2023197004A1 (en) | 2022-04-07 | 2023-10-12 | Guardant Health, Inc. | Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules |
| EP4532762A1 (en) * | 2022-06-02 | 2025-04-09 | The Board Of Trustees Of The Leland Stanford Junior University | Single molecule sequencing and methylation profiling of cell-free dna |
| WO2024006908A1 (en) | 2022-06-30 | 2024-01-04 | Guardant Health, Inc. | Enrichment of aberrantly methylated dna |
| US20240043935A1 (en) * | 2022-07-29 | 2024-02-08 | Centre For Novostics Limited | Epigenetics analysis of cell-free dna |
| WO2024073508A2 (en) | 2022-09-27 | 2024-04-04 | Guardant Health, Inc. | Methods and compositions for quantifying immune cell dna |
| CN115295074B (zh) * | 2022-10-08 | 2022-12-16 | 南京世和基因生物技术股份有限公司 | 基因标志物在恶性肺结节筛查中的应用、筛查模型的构建方法和检测装置 |
| WO2024138180A2 (en) | 2022-12-22 | 2024-06-27 | Guardant Health, Inc. | Integrated targeted and whole genome somatic and dna methylation sequencing workflows |
| WO2024137880A2 (en) | 2022-12-22 | 2024-06-27 | Guardant Health, Inc. | Methods involving methylation preserving amplification with error correction |
| WO2024233502A1 (en) | 2023-05-05 | 2024-11-14 | Guardant Health, Inc. | Cell-free dna blood-based test for cancer screening |
| WO2025019370A1 (en) * | 2023-07-14 | 2025-01-23 | Natera, Inc. | Methods for assaying circulating tumor dna |
| WO2025029475A1 (en) | 2023-07-28 | 2025-02-06 | Guardant Health, Inc. | Methods to enrich nucleotide variants by negative selection |
| WO2025038399A1 (en) | 2023-08-11 | 2025-02-20 | Guardant Health, Inc. | Methylated enrichment methods for single-molecule genetic and epigenetic sequencing |
| CN117230165A (zh) * | 2023-09-01 | 2023-12-15 | 深圳湾实验室 | 一种无创产前检测胎儿染色体拷贝数异常的优化方法 |
| WO2025064706A1 (en) | 2023-09-19 | 2025-03-27 | Guardant Health, Inc. | Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules |
| WO2025076452A1 (en) | 2023-10-06 | 2025-04-10 | Guardant Health, Inc. | Detecting tumor-related information based on methylation status of cell-free nucleic acid molecules |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9218449B2 (en) * | 2007-07-23 | 2015-12-22 | The Chinese University Of Hong Kong | Methods for analyzing massively parallel sequencing data for noninvasive prenatal diagnosis |
| CA2741117A1 (en) * | 2008-10-30 | 2010-05-06 | Centre De Recherche Public De La Sante | Biomarkers for heart failure |
| CN101901345B (zh) * | 2009-05-27 | 2013-02-27 | 复旦大学 | 一种差异蛋白质组学的分类方法 |
| US11322224B2 (en) * | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| EP2426217A1 (en) * | 2010-09-03 | 2012-03-07 | Centre National de la Recherche Scientifique (CNRS) | Analytical methods for cell free nucleic acids and applications |
| WO2013015793A1 (en) * | 2011-07-26 | 2013-01-31 | Verinata Health, Inc. | Method for determining the presence or absence of different aneuploidies in a sample |
| WO2013052913A2 (en) * | 2011-10-06 | 2013-04-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US9367663B2 (en) * | 2011-10-06 | 2016-06-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| BR112014020211A2 (pt) * | 2012-02-16 | 2017-07-04 | Oxford Nanopore Tech Ltd | métodos para analisar uma série ordenada por tempo de medições de um polímero, para estimar a presença, ausência ou quantidade de um polímero alvo, e para determinar uma alteração em um polímero, programa de computador, e, dispositivos de análise e de diagnóstico |
| CN107435070A (zh) * | 2012-04-12 | 2017-12-05 | 维里纳塔健康公司 | 拷贝数变异的检测和分类 |
| US10497461B2 (en) * | 2012-06-22 | 2019-12-03 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2014149134A2 (en) * | 2013-03-15 | 2014-09-25 | Guardant Health Inc. | Systems and methods to detect rare mutations and copy number variation |
| US20160040229A1 (en) * | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| WO2014039556A1 (en) | 2012-09-04 | 2014-03-13 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US20130309666A1 (en) * | 2013-01-25 | 2013-11-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| AU2014281635B2 (en) * | 2013-06-17 | 2020-05-28 | Verinata Health, Inc. | Method for determining copy number variations in sex chromosomes |
| US9499870B2 (en) * | 2013-09-27 | 2016-11-22 | Natera, Inc. | Cell free DNA diagnostic testing standards |
| CN111534580B (zh) | 2013-12-28 | 2024-06-04 | 夸登特健康公司 | 用于检测遗传变异的方法和系统 |
| KR102566176B1 (ko) * | 2014-05-30 | 2023-08-10 | 베리나타 헬스, 인코포레이티드 | 태아 아-염색체 홀배수체 및 복제수 변이 탐지 |
| JP2017522908A (ja) * | 2014-07-25 | 2017-08-17 | ユニヴァーシティ オブ ワシントン | セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法 |
| EP3502273B1 (en) * | 2014-12-12 | 2020-07-08 | Verinata Health, Inc. | Cell-free dna fragment |
-
2017
- 2017-07-06 AU AU2017292854A patent/AU2017292854B2/en active Active
- 2017-07-06 CA CA3030038A patent/CA3030038A1/en active Pending
- 2017-07-06 EP EP23202039.6A patent/EP4322168A3/en active Pending
- 2017-07-06 WO PCT/US2017/040986 patent/WO2018009723A1/en unknown
- 2017-07-06 BR BR112019000296-0A patent/BR112019000296A2/pt unknown
- 2017-07-06 JP JP2018568937A patent/JP7448310B2/ja active Active
- 2017-07-06 CN CN201780054825.3A patent/CN109689891B/zh active Active
- 2017-07-06 SG SG11201811556RA patent/SG11201811556RA/en unknown
- 2017-07-06 KR KR1020197003420A patent/KR102610098B1/ko active Active
- 2017-07-06 ES ES17824931T patent/ES2967443T3/es active Active
- 2017-07-06 MX MX2019000037A patent/MX2019000037A/es unknown
- 2017-07-06 EP EP17824931.4A patent/EP3481966B1/en active Active
-
2021
- 2021-10-26 JP JP2021174556A patent/JP2022025101A/ja not_active Withdrawn
-
2024
- 2024-06-05 JP JP2024091417A patent/JP2024119898A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017292854A1 (en) | 2019-01-24 |
| KR20190026837A (ko) | 2019-03-13 |
| EP3481966A1 (en) | 2019-05-15 |
| CN109689891A (zh) | 2019-04-26 |
| ES2967443T3 (es) | 2024-04-30 |
| EP3481966B1 (en) | 2023-11-08 |
| EP4322168A3 (en) | 2024-05-15 |
| JP7448310B2 (ja) | 2024-03-12 |
| WO2018009723A1 (en) | 2018-01-11 |
| JP2019531700A (ja) | 2019-11-07 |
| EP3481966A4 (en) | 2019-08-07 |
| SG11201811556RA (en) | 2019-01-30 |
| KR102610098B1 (ko) | 2023-12-04 |
| JP2022025101A (ja) | 2022-02-09 |
| AU2017292854B2 (en) | 2023-08-17 |
| EP4322168A2 (en) | 2024-02-14 |
| BR112019000296A2 (pt) | 2019-04-16 |
| CN109689891B (zh) | 2024-06-18 |
| CA3030038A1 (en) | 2018-01-11 |
| JP2024119898A (ja) | 2024-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000037A (es) | Metodos para perfilado de fragmentoma de acidos nucleicos libres de celula. | |
| EP4269577A3 (en) | Nucleobase editors and uses thereof | |
| MX2023014124A (es) | Identificacion, fabricacion y uso de neoantigeno. | |
| FI3604532T3 (fi) | Uusia crispr-entsyymejä ja järjestelmiä | |
| MX2016016713A (es) | Procesos y sistemas para el montaje de secuencias de acido nucleico. | |
| AU2017257225A1 (en) | Allele editing and applications thereof | |
| WO2019108555A8 (en) | Models for targeted sequencing | |
| MX2015017110A (es) | Integracion dirigida. | |
| HK1258869A1 (zh) | 寡核酸變體文庫及其合成 | |
| EP4428863A3 (en) | Methods and compositions for determining ploidy | |
| CA2983023A1 (en) | Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids | |
| BR112015012375A2 (pt) | modificação e regulação de genoma à base de crispr | |
| MX2022009242A (es) | Producto en desarrollo de analisis de secuenciacion de alineacion y variante. | |
| SG10201809564YA (en) | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof | |
| EP3699280A3 (en) | Novel cas9 systems and methods of use | |
| EA201992795A1 (ru) | Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе | |
| WO2014145820A3 (en) | Multiple tagging of long dna fragments | |
| MX2018001617A (es) | Composiciones de crispr-cas9 diseñados y metodos de uso. | |
| EP4375373A3 (en) | Cas variants for gene editing | |
| NZ728437A (en) | Methods for increasing cas9-mediated engineering efficiency | |
| HK1246180A1 (zh) | 使用自然殺傷細胞治療血液病症、實體瘤或感染性疾病的方法 | |
| WO2018170614A8 (zh) | 基因组大片段直接克隆和dna多分子组装新技术 | |
| WO2014116729A3 (en) | Haplotying of hla loci with ultra-deep shotgun sequencing | |
| HRP20211419T1 (hr) | Predviđanje epitopa t-stanica korisnih za cijepljenje | |
| EP3845640A3 (en) | Modified tranposases for improved insertion sequence bias and increased dna input tolerence |